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To investigate the regulatory mechanisms of telo-
merase activity in human melanoma cells, we
assessed the enzyme's catalytic activity and the
expression of the telomerase subunits, the human tel-
omerase RNA, the human telomerase-associated
protein, and the human telomerase reverse transcrip-
tase, in 52 melanoma lesions. Eight normal skin
specimens were also studied. Telomerase activity was
detected in 84.6% of melanomas, whereas all skin
specimens were telomerase negative. Human telo-
merase-associated protein mRNA and human telo-
merase RNA were constitutively expressed in all
melanoma and skin specimens. Although at a vari-
able level of expression, human telomerase reverse
transcriptase mRNA was detected in all but one
melanomas, whereas it was never present in skin
samples. Reverse transcriptase±polymerase chain
reaction experiments were performed using primers
within the reverse transcriptase domain of human
telomerase reverse transcriptase and revealed the
presence of multiple alternatively spliced transcripts
in melanoma specimens. Among the 44 telomerase-
positive melanomas, one showed the full-length
transcript alone whereas in all other specimens a full-
length message was present with different combin-
ations of alternatively spliced variants. In these
tumors the expression of the full-length transcript
was generally equal to or higher than that of the
alternatively spliced variants. The ratio full-length
transcript to alternatively spliced species ranged from
0.6 to 5.26, with a median value of 1.18. Among the
seven telomerase-negative melanomas, one displayed
the b deletion transcript alone, whereas in the
remaining six tumors weak expression of the full-
length transcript and a more abundant level of
alternatively spliced transcripts were found. In these
cases human telomerase reverse transcriptase ratio
ranged from 0.09 to 1.1, with a median value of
0.40. The results suggest that transcription and
alternative splicing of human telomerase reverse
transcriptase are regulatory mechanisms controlling
telomerase activity in melanoma. Key words: altern-
atively spliced human telomerase reverse transcriptase vari-
ants/telomerase subunits. J Invest Dermatol 116:867±873,
2001
H
uman telomeres are specialized structures consisting
of tandem repeats of the hexanucleotide sequence
5¢-TTAGGG-3¢ and associated proteins, which cap
both ends of chromosomes and protect them from
degradation and end-to-end fusion (Blackburn,
1991). Telomeres shorten with each round of DNA replication as a
consequence of the inability of conventional DNA polymerases to
copy the extreme ends of linear chromosomes (Watson, 1972). In
the absence of a compensatory mechanism, telomere shortening
results in chromosomal instability, which leads to replicative
cellular senescence (Harley, 1991; Allsopp et al, 1992).
Telomerase provides the enzymatic activity that compensates for
telomere shortening in germ-line cells and cancer cells (Counter
et al, 1992; Kim et al, 1994; Greider, 1998). The almost ubiquitous
expression of telomerase in human tumors and not in somatic cells
supports the hypothesis that the enzyme is involved in cellular
immortality and carcinogenesis (Rhyu, 1995). Moreover, Hahn et al
(1999) have recently demonstrated that ectopic expression of the
catalytic telomerase subunit in combination with two oncogenes
(SV 40 large-T and H-ras) resulted in direct tumorigenic
conversion of normal human epithelial and ®broblast cells.
Human telomerase is a large ribonucleoprotein complex com-
posed of at least three components: the RNA subunit hTR, which
contains the template sequence coding for telomere repeats (Feng
et al, 1995); the catalytic subunit hTERT, which possesses
conserved reverse transcriptase motifs (Harrington et al, 1997a;
Meyerson et al, 1997; Nakamura et al, 1997); and the telomerase-
associated protein hTEP1, which may play a part in co-ordinating
the telomerase holoenzyme structure and/or recruiting telomerase
regulatory factors (Harrington et al, 1997b). Whereas hTR and
hTEP1 are widely expressed in normal cells (Feng et al, 1995;
Harrington et al, 1997a), the expression of hTERT is repressed in
most human somatic tissues (Nakamura et al, 1997) and becomes
reactivated in the great majority of human tumors and immortal
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cell lines (Meyerson et al, 1997; Kyo et al, 1999). Moreover, a
strong correlation has been observed between telomerase activity
and hTERT mRNA expression in many immortalized and tumor
cell models (Harrington et al, 1997a; Meyerson et al, 1997;
Nakamura et al, 1997), which would suggest that expression of
hTERT is the rate-limiting step in telomerase activation.
The potential mechanisms of regulation of telomerase activity
have been addressed in many recent studies. Speci®cally, it has been
demonstrated that the hTERT promoter contains binding sites for
several transcription factors (Cong et al, 1999; Wick et al, 1999; Wu
KJ et al, 1999), suggesting that hTERT expression may be subject
to multiple levels of control and regulated by different factors in
different cellular contexts. Moreover, it has been proposed that,
besides gene transcription, alternative splicing of hTERT tran-
scripts can also regulate telomerase activity (Ulaner et al, 1998). The
function of the alternatively spliced variants is currently unknown;
however, as several of the splice sites remove reverse transcriptase
motifs (Fig 1), these transcripts probably do not code for functional
reverse transcriptase. Suppression of telomerase activity during fetal
kidney development is associated with this mechanism (Ulaner et al,
1998). It has recently been demonstrated that such a mechanism for
regulating telomerase activity is also operative in normal and
neoplastic ovarian and uterine tissues (Ulaner et al, 2000). Protein
phosphorylation also seems to be an important post-translational
mechanism controlling the structure and function of telomerase (Li
et al, 1997; Li et al, 1998; Kang et al, 1999). Moreover, proteins
associated with telomeres, such as TRF1 (van Steensel and de
Lange, 1997) and the poly(adenosine diphosphate-ribose) poly-
merase tankyrase (Smith et al, 1998), are thought to play a crucial
part in the control of telomerase activity.
This study aimed to investigate the possible mechanisms of
regulation of telomerase activity in human melanoma tissues by
correlating the catalytic activity of the enzyme with the expression
of the three telomerase subunits, hTERT, hTR, and hTEP1, as
well as with the presence of alternatively spliced hTERT variants.
MATERIAL AND METHODS
Tumor material and cell lines Tumor lesions (36 lymph node
metastases and 16 cutaneous/subcutaneous metastases) were obtained
from 52 patients with cutaneous melanoma at stages III (43 cases) and IV
(nine cases). For four patients, two synchronous metastatic lesions were
tested. Forty patients underwent surgery alone, four patients had also
been previously treated with immunotherapy (interferon-a or
interleukin-12) and eight patients with chemotherapy (dacarbazine).
Eight normal skin specimens were also obtained from the abdomen or
breast of patients who underwent surgery for aesthetic purposes. Tissue
were obtained at the time of surgery and then ¯ash-frozen in liquid
nitrogen. All tissues underwent histologic examination and were stored at
±80°C until use. In particular, to con®rm the representativeness of the
tumor tissue sampled for molecular analyses, quality control was
performed on frozen sections, stained with hematoxylin±eosin, before
performing telomerase analysis. For each case, telomerase activity and
telomerase component RNA expression were determined in two
contiguous pieces of the same tumor lesion.
The human melanoma cell line JR8 (Zupi et al, 1985) and the
immortalized ®broblast cell line GM847 (Perrem et al, 1999) were used
as positive and negative controls for telomerase activity and hTERT
gene expression, respectively.
Telomerase activity detection assay Cell extracts were obtained as
previously described (Villa et al, 1998). Telomerase activity was measured
by the polymerase chain reaction (PCR) -based telomeric-repeat
ampli®cation protocol (TRAP) with some modi®cations (Kim et al,
1994). Samples containing 0.06, 0.6, and 6 mg of protein were analyzed
in the TRAP reaction for each tissue specimen by the TRAPeze kit
(Intergen, Oxford, U.K.) according to the manufacturer's protocol. After
extension of the substrate TS (5¢-AATCCGTCGAGCAGAGTT-3¢)
oligonucleotide by telomerase, the telomerase products were ampli®ed
by PCR in the presence of 5¢-[32P]-end-labeled TS primer for 30 cycles
and resolved in 10% polyacrylamide gels. Each reaction product was
ampli®ed in the presence of a 36 bp internal TRAP assay standard, and
each sample extract was tested for RNase sensitivity. A TSR8
quantitation standard (which serves as a standard to estimate the amount
of product extended by telomerase in a given extract) was included for
each set of TRAP assays. Quantitative analysis was performed with the
Image-QuanT software (Molecular Dynamics, Sunnyvale, CA), which
allowed densitometric evaluation of the digitized image. Telomerase
activity was quanti®ed by measuring the signal of telomerase ladder
bands and calculated as the ratio to the internal standard using the
following formula:
relative telomerase activity: ((X ± X0)/C) 3 ((R ± R0)/Cr)
± 1
where X is the untreated sample, X0 is the RNase-treated sample, C is
the internal control of untreated samples, Cr is the internal control of
TSR8, R is the TSR8 quantitation control, and R0 is the negative
control. Telomerase activity obtained with 1.0 mg of protein extract
from the JR8 melanoma cell line was arbitrarily de®ned as 1.00 unit.
The relative telomerase activity of each tissue sample represents the ratio
between the arbitrary unit of the tested sample and that of JR8 cells.
RNA extraction and reverse transcriptase±PCR analysis of telomer-
ase components Total cellular RNA was extracted from frozen
samples with the TRIzol reagent (Life Technologies, Gaithersburg, MD)
according to the manufacturer's instructions. Total RNA (0.5 mg) from
each sample was used for c-DNA production using the reverse
transcriptase±PCR Core kit (Perkin Elmer, Branchburg, NJ) with
random hexamers. The cDNA samples were then ampli®ed with the
same kit. Speci®cally, hTR cDNA was ampli®ed using TR-46S (5¢-
CTAACCCTAACTGAGAAGGGCGTAG-3¢) and TR-148AS (5¢-
GAAGGCGGCAGGCCGAGGCTTTTCC-3¢) oligonucleotides with an
initial heating at 95°C for 3 min, followed by 28 cycles of 95°C for
30 s, 65°C for 45 s, 72°C for 30 s, and 72° for 5 min. Primers 5899S
Figure 1. Diagram of the hTERT mRNA.
Sequence numbering is based on GenBank
Database accession number AF15950(Nakamura et
al, 1997). Conserved reverse transcriptase motifs
are labeled 1, 2, and A±E. TERT-1784S and
TERT-1929AS primers amplify a 145 bp
fragment from a region near the 5¢ end of the
reverse transcriptase domain whereas TERT-
2164S and TERT-2620AS primers amplify a
region containing the A and B motifs. Alternative
splicing of hTERT mRNA results in the four
hTERT PCR products referred to in this study.
Splicing at the a site results in a 36 base (12
amino acids) deletion within the A motif. Splicing
at the b site removes 182 bases and causes a non-
sense mutation, truncating the protein before the
B±E motifs (Ulaner et al, 2000). In this report we
designate as full length hTERT mRNA that is
complete from base 2164 to base 2620 (457 bp).
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and 5900AS (Ulaner et al, 1998) were added at 72°C of cycle 7 for the
b-actin internal control. TEP1 cDNA was ampli®ed using TEP1-S (5¢-
TCAAGCCAAACCTGAATC-
TGAG-3¢) and TEP1-AS (5¢-CCCCGAGTGAATCTTTCTACGC-3¢)
oligonucleotides (Ramakrishnan et al, 1998) with an initial heating at
95°C for 3 min, followed by 30 cycles of 95°C for 30 s, 62°C for 45 s,
72°C for 30 s, and 72°C for 5 min. Primers 774 A and 775AS (Ulaner
et al, 1998) were added at 72°C of cycle 10 for the b-actin internal
control. The ®rst hTERT cDNA ampli®cation used TERT-1784S (5¢-
CGGAAGAGTGTCTGGAGCAA-3¢) and TERT-1929AS (5¢-GGA-
TGAAGCGGAGTCTGGA-3¢) oligonucleotides with an initial heating
at 95°C for 3 min, followed by 33 cycles of 95°C for 30 s, 65°C for
45 s, 72°C for 30 s, and 72°C for 5 min. Primers 774S and 775AS were
added at 72°C of cycle 13 for internal control. The PCR products were
electrophoresed on a 3% agarose gel and visualized with ethidium
bromide. Ampli®cation of alternatively spliced hTERT cDNA (Fig 1)
was obtained using TERT-2164S (5¢-GCCTGAGCTGTACTTTGT-
CAA-3¢) and TERT-2620AS (5¢-CGCAAACAGCTTGTTCTCCAT-
GTC-3¢) oligonucleotides with initial heating at 95°C for 3 min,
followed by 35 cycles of 95°C for 30 s, 62°C for 50 s, 72°C for 50 s,
and 72°C for 5 min. The ampli®cation was performed in a mixture
containing 0.3 mCi of [a-32P]deoxycytidine triphosphate (300 Ci per
mmol; Amersham Pharmacia Biotech, Cologno Monzese, Milan, Italy).
Primers 774S and 775AS were added at 72°C of cycle 25 for internal
control. Reverse transcriptase±PCR experiments were performed in
duplicate. Ampli®ed products were electrophoresed on 5% non-
denaturing polyacrylamide gel in 1 3 Tris±borate ethylenediamine
tetraacetic acid buffer (90 mM Tris±borate, pH 8.3, 2 mM ethylene-
diamine tetraacetic acid). The gel was dried and autoradiographed. All
ampli®ed products were analyzed by a ScanJET IIcx/T scanner (Hewlett
Packard, Milan, Italy) and quanti®ed by ImageQuant software. To
evaluate the relative levels of expression of the target genes, the value of
the internal standard (b-actin) in each test-tube was used as the baseline
gene expression in that samples and the relative value was calculated for
each of the target genes (densitometric value of the target gene/
densitometric value of b-actin). The values were then used to compare
expression across tested samples. The hTERT ratio (calculated by
dividing the expression value of the full-length transcript signal by that of
the alternatively spliced species) was also determined for each tissue
sample.
Thymidine labeling index (TLI) Small fragments of fresh tumor
material were incubated with 3H-thymidine, ®xed for 6±10 h in buffered
formalin, and processed by autoradiography as previously described
(Costa et al, 1990). TLI was assessed by scoring a total of 1000±3000
tumor cells and de®ned as the percentage ratio between labeled tumor
cells and total number of tumor cells.
Statistical analysis Spearman's regression analysis was used to evaluate
the relationship between telomerase activity and hTERT mRNA
expression in individual melanoma lesions. Wilcoxon's rank sum test was
used to compare the hTERT ratios in the two subsets of telomerase-
positive and telomerase-negative tumors.
RESULTS
Telomerase activity in melanoma and normal skin
specimens Telomerase activity and expression of the hTR,
hTEP1, and hTERT telomerase subunits were determined in a
series of 52 human metastatic malignant melanomas (36 lymph
node metastases and 16 cutaneous/subcutaneous metastases) and
eight normal skin samples. Telomerase activity was measured by the
TRAP assay, and the reliability of the assay was investigated by
testing three different protein concentrations (0.06, 0.6, and 6 mg)
for each tissue sample (Fig 2). We failed to evidence any
telomerase activity at any protein concentration in eight of 52
(15.4%) melanomas, whereas the other 44 cases (84.6%) displayed a
positive TRAP signal of at least one protein concentration.
Speci®cally, 10 tumors (19.2%) showed positivity only at the
highest protein concentration, 14 tumors (26.9%) gave a positive
TRAP signal when 0.6 and 6 mg of protein were used, and the
remaining 20 tumors (39.4%) were positive at all protein
concentrations. In no case was a tumor that showed telomerase
activity at the protein concentration of 0.6 mg negative at the
highest protein concentration. The ®nding would exclude the
possibility of false-negative results. Moreover, results obtained in
individual specimens showed that the extent of the TRAP signal
was highly dependent on protein concentration. As a consequence,
TRAP results obtained with 6 mg of protein were considered as the
best indicator of enzyme activity, and the concentration used to
compare telomerase activity across samples. For this purpose, data
were expressed as relative values with respect to the activity
(arbitrarily de®ned as 1.00 unit) observed in the JR8 human
melanoma cell line, which was used as an external control
throughout the study. Results revealed the presence of a variable
degree of telomerase catalytic activity, ranging from 0.18 to
1.42 units (with standard deviations, calculated on three replicates
of each samples, ranging from 1.0 to 34% of the mean values), in
the 44 telomerase-positive melanomas. Conversely, no telomerase
activity was found in any of the normal skin samples at any protein
concentration tested. No signi®cant differences in the frequency of
telomerase-positive lesions or in the level of telomerase activity was
observed between the two types of metastasis. Speci®cally, 30 of 36
(83%) lymph node metastases and 14 of 16 (87.5%) cutaneous
metastases were positive for telomerase activity and displayed a
median enzyme catalytic activity of 0.48 and 0.45 unit, respectively.
Moreover, no difference in the rate of melanoma cell proliferation,
determined as TLI, was found as a function of telomerase activity.
In fact, the median TLI values were 6.86% and 7.34% in telomerase-
positive and telomerase-negative melanomas, respectively. No
association was observed when TLI values and the levels of
telomerase catalytic activity were matched in individual tumors.
Expression of hTR, hTEP1 mRNA, and hTERT mRNA in
melanoma and normal skin samples The optimal conditions
for the detection of hTR and hTEP1 expression by reverse
transcriptase±PCR, in terms of PCR cycles and starting RNA
amount, were ®rst optimized by using the JR8 human melanoma
cell line (data not shown). Reverse transcriptase±PCR experiments
carried out on clinical specimens indicated that all melanoma and
normal skin samples constitutively expressed hTR and hTEP1
mRNA (Fig 3B). As regards hTERT, the mRNA was initially
measured with primers for a region of the transcript upstream from
the reverse transcriptase domain (hTERT-1784S and TERT-
1929AS) (Fig 1). Also for this gene, the optimal conditions for
reverse transcriptase±PCR experiments were de®ned on JR8 cells;
however, as hTERT is generally expressed at very low levels in
Figure 2. Telomerase activity of human melanomas as detected
by the TRAP assay. A representative series of human melanomas is
shown, in which telomerase activity was measured using different protein
concentrations (0.06, 0.6, and 6.0 mg). Samples A±D correspond to
samples 4, 11, 7, and 8 reported in Fig 3. The lane indicated as JR8
represents a positive control containing 1.0 mg cell extract of the
telomerase-positive JR8 melanoma cell line. The lane indicated +RNase
represents a negative control containing JR8 cell extract pretreated with
RNase. Blank represents a negative control to which no cell extract was
added; R8 represents an external quantitative standard. The location of
the internal ampli®cation standard is indicated.
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human tumors, the adequacy of the amount of starting RNA was
veri®ed in a subset of 10 melanomas. A progressive increase in the
quantity of PCR products by increasing the amount of starting
RNA was observed in the range of 0.05±0.8 mg when the target
(hTERT) and the reference (b-actin) genes were coampli®ed in the
same tube (Fig 4). Only one of 52 melanomas did not express
hTERT mRNA (Fig 3B, sample 5), and there was no telomerase
activity in this sample (Fig 3A, sample 5). All the other melanoma
samples expressed hTERT mRNA albeit to a variable extent,
ranging from 0.10 to 1.20 arbitrary densitometric units relative to
the b-actin gene, when evaluated using a starting RNA amount of
0.5 mg. Moreover, a trend towards an association between the level
of hTERT mRNA expression and that of telomerase catalytic
activity (rs = 0.34; p = 0.08) was evidenced in the 44 telomerase-
positive hTERT-expressing melanomas. The association reached
statistical signi®cance (rs = 0.49; p = 0.010) in the subset of lymph
node metastases. Seven of eight melanomas that were negative for
telomerase activity expressed hTERT mRNA (Fig 3B,
representative samples 1, 3, and 9), whereas no hTERT mRNA
signal was observed in normal skin samples (Fig 3B, representative
samples 13±16). No association was observed between proliferative
activity, in terms of TLI, and hTERT mRNA levels in individual
melanomas.
Alternative splicing of hTERT in melanoma samples As it
has been demonstrated that alternative splicing of hTERT
transcripts is involved in the regulation of telomerase activity, we
subsequently performed reverse transcriptase±PCR experiments by
using a primer set for the reverse transcriptase domain of the
hTERT transcript (hTERT 2164S and hTERT 2620AS), which
contains two potential splice sites (Fig 1). Speci®cally, the a splice
causes a 36 bp deletion (bases 2186±2221) of the conserved reverse
transcriptase motif A, and the b splice causes a 182 bp deletion
(bases 2342±2524) resulting in a non-sense mutation, truncating the
protein before the conserved reverse transcriptase motifs B, C,
and D.
Reverse transcriptase±PCR experiments with the 2164/2620
primer set generated four products that represent the full-length
hTERT transcript (457 bp), the a deletion transcript (421 bp), the
b deletion transcript (275 bp) and the a + b deletion transcript
(239 bp). Representative examples of the different situations are
given in Fig 3(C). The reverse transcriptase±PCR results revealed
alternative splicing of the hTERT transcripts in 51 melanomas. As
expected, no PCR products were seen in one melanoma sample
(Fig 3C, sample 5) and in the eight normal skin samples (Fig 3C,
representative samples 13±16).
As regards the 44 melanomas expressing telomerase activity, one
tumor showed the presence of the full-length transcript alone
(Fig 3C, sample 10) and in the other 43 specimens the full-length
transcript was present with different combinations of a, b, or a + b
deletion transcripts, although a prevalence of the b deletion
transcript was observed. Densitometric analysis revealed that in
these tumors the expression of the full-length transcript was
generally equal to or higher than that of the alternatively spliced
variants, with hTERT ratios (calculated by dividing the densito-
Figure 3. Telomerase activity and expression of hTR, hTEP1,
and hTERT telomerase subunits in human melanoma and
normal skin. A representative series of melanoma (samples 1±12) and
normal skin specimens (samples 13±16) is shown. (A) Telomerase activity
was measured by the TRAP assay. (B) Expression of hTR, hTEP1
mRNA, and hTERT mRNA as detected by reverse transcriptase±PCR.
hTERT mRNA was measured using TERT-1784S and TERT 1929AS
primers. All telomerase subunits were coampli®ed with b-actin as the
internal standard. (C) Expression and alternative splicing variants of
hTERT as detected by reverse transcriptase±PCR using TERT-2164S
and TERT-2620AS primers. The positions of the full-length (457 bp), a
spliced (421 bp), b spliced (275 bp) and a + b spliced (239 bp) messages
are indicated.
Figure 4. Quanti®cation of hTERT gene expression by reverse
transcriptase±PCR in human melanomas. (A) Densitometric
quanti®cation of PCR products for target (hTERT) and reference
(b-actin) genes as a function of the amount of starting RNA in a
representative series of melanomas. Data represent mean 6 SD obtained
from three replicates. (B) Examples of coampli®cation of hTERT and
b-actin genes in melanoma samples. The b-actin primers were added at
the 13th cycle.
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metric value of the full-length transcript signal by that of the
alternative splicing species) ranging from 0.6 to 5.26 and a median
value of 1.18 (Table I). As regards the seven melanomas that did
not express telomerase activity, in one case only was the b deletion
transcript observed (Fig 3C, sample 9). In the remaining six tumors
weak expression of the full-length transcript and a more marked
abundance of alternatively spliced transcripts (particularly the b
deletion transcript) were found. In these cases the hTERT ratios
ranged from 0.09 to 1.1 with a median value of 0.40 (Table II) and
were signi®cantly (p < 0.01) different from those observed in
melanomas expressing telomerase activity.
Interlesion tumor heterogeneity as regards telomerase
activity and hTERT expression In an attempt to evaluate
possible interlesion tumor heterogeneity, we tested two
synchronous metastases from four melanoma patients for
telomerase activity and hTERT expression. In two patients both
the lesions were cutaneous/subcutaneous metastases, whereas in
each of the other two patients, one lymph node and one cutaneous
metastases were assayed. In three patients, telomerase activity was
detected in both the lesions, and the level of expression of the full-
length hTERT transcript was always higher than that of splicing
variants (with hTERT ratios ranging from 1.25 to 3.1). As regards
the variants, only the b deletion transcript was consistently observed
in two patients whereas, in the third patient, also the a + b variant
was detected in one lesion. A lack of telomerase activity was
observed in the lymph node lesion of the fourth patient, which also
showed a weak expression of the full-length hTERT message and a
more marked abundance of the b deletion transcript (hTERT ratio,
0.4). Conversely, telomerase activity was detected in the
synchronous cutaneous lesion, in which full-length hTERT
transcript and b spliced variant were expressed at comparable
levels (hTERT ratio, 1.2).
DISCUSSION
Knowledge of the mechanisms by which human telomerase is
regulated appears of the utmost importance for a better under-
standing of processes leading to tumorigenesis. To gain insight into
the mechanisms regulating telomerase in human cutaneous mela-
noma, we examined the catalytic activity of the enzyme in relation
to the expression of the hTR, hTEP1, and hTERT telomerase
subunits in metastatic melanoma lesions and, for comparative
purposes, in normal skin samples.
Telomerase activity was detected in 85% of the melanoma
lesions, in accordance with the results obtained in the few
previously published studies conducted on a smaller series of
cases, which indicated a percentage of telomerase-positive mela-
nomas ranging from 69% to 92% (Taylor et al, 1996; Glaessl et al,
1999; Parris et al, 1999). Conversely, we did not detect telomerase
activity in normal skin samples. Previous studies have reported the
presence of telomerase activity in a variable percentage (from 0 to
44%) of normal skin samples. Such an activity seems to be strongly
associated with the level of sun exposure. In fact, it has been
reported that 33±54% of skin samples from chronically exposed sites
were telomerase positive compared with 0±12% of samples from
covered sites (Ueda et al., 1997; Wu A et al, 1999). Moreover, by
dissecting human skin, Harle-Bachor and Boukamp (1996) were
able to demonstrate that epidermis, but not dermis, exhibits
telomerase activity, and that within the epidermis, enzyme activity
is restricted to the basal layer. As a consequence, discrepancies in
the results obtained in published studies can also partially be
explained by a different amount of connective tissue, with respect
to epidermis, present in the lesions.
In individual melanomas, we failed to observe any correlation
between telomerase activity and TLI proliferation index. Lack of a
correlation between telomerase activity and growth fraction has
also been reported in a series of human uveal melanomas (Heine
et al, 2000). No signi®cant differences in cell characteristics related
to differentiation, such as melanin content, were observed between
telomerase-positive and telomerase-negative lesions, thus indicating
that, at least in our case series, telomerase activity was not associated
with differentiation.
In our case series, there was no signi®cant difference in clinical
outcome of patients with telomerase-negative tumors with respect
to those with telomerase-positive melanomas; however, it should
be stressed that a degree of interlesion heterogeneity as regards
telomerase activity (as well as hTERT expression) may exist, as we
observed in the small series of melanomas in which two
synchronous metastases were comparatively assayed. As a conse-
quence, a possible clinical relevance of telomerase data obtained on
a single lesion can be biased by the presence of such heterogeneity.
We found that hTR and hTEP1 mRNA were constitutively
expressed in normal skin and human melanoma specimens
independently of the presence of telomerase activity. This ®nding
is in keeping with the results of previous studies indicating that
neither hTR nor hTEP1 expression correlated with telomerase
activity in several cellular models (Ito et al, 1998; Kanaya et al, 1998;
Kyo et al, 1999; Sumida et al, 1999). Conversely, the presence of
hTERT mRNA was necessary, although not suf®cient, to activate
telomerase in melanomas. Recent reports have shown a close
correlation between telomerase activity and hTERT mRNA
expression in different tumor types (Ito et al, 1998; Kanaya et al,
1998; Kyo et al, 1999; Sumida et al, 1999), thus identifying
transcription of the hTERT gene as a major regulatory step in the
process of telomerase reactivation. Forced expression of hTERT in
normal and transformed cells without detectable telomerase results
in the restoration of telomerase activity and permits cells to
proliferate inde®nitely (Bodnar et al, 1998). These observations
support the notion that activation of hTERT transcription may
represent a critical event in tumor progression.
The presence of hTERT mRNA was not always suf®cient to
account for telomerase activity in melanoma lesions. The discrep-
Table I. Expression and alternative splicing of hTERT





Median Mean 6 SD Range
Full-length message 1
Full-length
+b spliced messages 24 1.47 1.57 6 1.12 0.60±5.26
+b + (a + b)
spliced messages 9 0.92 0.93 6 0.27 0.60±1.29
+all spliced messages 10 0.95 1.04 6 0.22 0.83±1.40
Overall 43 1.18 1.31 6 0.89 0.60±5.26
aThe hTERT ratio was calculated as the radiodensitometric value for the full-
length transcript divided by the value for the alternatively spliced variants.
Table II. Expression and alternative splicing of hTERT




Median Mean 6 SD Range
b spliced message 1
Full-length
+b spliced messages 5 0.38 0.45 6 0.38 0.09±1.10
+b + (a + b)
spliced messages 1 0.61
Overall 6 0.40 0.48 6 0.35 0.09±1.10
aThe hTERT ratio was calculated as the radiodensitometric value for the full-
length transcript divided by the value for the alternatively spliced variants.
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ancy observed in some of our cases between telomerase activity and
the expression of hTERT mRNA could be explained, at least in
part, by the presence of intralesion heterogeneity as regards the two
parameters, as TRAP and reverse transcriptase±PCR determin-
ations were not performed on the same cells. As it has recently been
demonstrated that alternative splicing of the catalytic telomerase
subunit is an important mechanism of telomerase regulation in the
development of human fetal tissues (Ulaner et al, 1998), we studied
the presence of alternatively spliced variants in our series of
melanomas. hTERT messages with deleted critical reverse
transcriptase motifs were detected, albeit to a variable extent, in
almost all tumors. These hTERT variants include the hTERTa
with an in-frame deletion of 12 amino acids from the reverse
transcriptase domain A, and the hTERT b with a 182-nucleotide
deletion resulting in a premature stop codon. In particular, the b
spliced message has been demonstrated to be incapable of
reconstituting an active telomerase enzyme in vitro (Weinrich et al,
1997).
Melanomas expressing telomerase activity were characterized by
the presence of the complete hTERT message alone or together
with one or more alternatively spliced transcripts; however, in these
lesions the full-length hTERT transcript was generally more
abundant than or as abundant as the alternatively spliced variants.
Conversely, in melanomas lacking telomerase activity we found the
presence of an alternatively spliced message alone or a considerably
higher level of alternatively spliced species as compared with that of
the complete hTERT transcript. The ®nding could indicate the
involvement of alternative splicing of hTERT in the control of
telomerase activity in metastatic melanomas. The possibility of such
a mechanism of telomerase control has never been reported before
in cutaneous malignancies. In fact the involvement of alternative
splicing of hTERT in the regulation of enzyme catalytic activity
has only been addressed by Ulaner et al (2000) in ovarian and
uterine tumors. The authors demonstrated that telomerase activity
was only present in tumor tissues that expressed hTERT with
complete A and B motifs. As a consequence, a novel ®nding of our
study is that the presence of a full-length hTERT transcript is not
suf®cient to allow telomerase activity when a high abundance of
hTERT spliced variants are concomitantly present. It will be of
interest to ascertain whether alternatively spliced messages are
translated into proteins and lead to a variety of telomerase
ribonucleoproteins characterized by a different, if any, catalytic
activity. In fact, although it is unlikely that alternatively spliced
variants of hTERT code for catalytically active proteins, there is the
interesting possibility that they act as dominant negative inhibitors
of hTERT; however, whether such a dominant negative effect is
exerted by affecting translation or post-translation modi®cations of
the complete protein or by preventing the assembly of the active
telomerase complex needs to be investigated.
Although in this study we did not address this issue, it must be
stressed that telomerase activity appears subject to multiple levels of
control, which may operate differently in different cellular contexts
(Li et al, 1997, 1998; van Steensel and de Lange, 1997; Smith et al,
1998; Holt et al, 1999; Kang et al, 1999).
Overall, the results of our study suggest that both hTERT gene
transcription and alternative splicing of hTERT transcripts are
mechanisms that regulate telomerase activity in human melanoma.
More detailed information on this regulatory process in tumors
could be useful for the development of new anti-cancer strategies;
however, even though previous studies have demonstrated that
telomerase activity increases from benign melanocytic lesions to
atypical nevi and further to melanoma (Glaessl et al, 1999), and
therefore may play a part in tumorigenesis and tumor progression,
the actual relevance of telomerase activity in sustaining the growth
of melanoma cells remains to be demonstrated. In this respect we
have recently reported that in a human melanoma cell system the
inhibition of telomerase activity by a hammerhead ribozyme
targeting the RNA component of the ribonucleoprotein did not
result in any telomere shortening and only slightly reduced the
cellular proliferative capacity (Folini et al, 2000). This ®nding might
tentatively be explained by the concomitant expression of
mechanisms other than telomerase (Bryan et al, 1997), which
could be responsible for the maintenance of telomeres in melanoma
cells. The presence of human melanoma specimens that do not
express telomerase activity, as reported by us and other authors
(Taylor et al, 1996; Glaessl et al, 1999; Parris et al, 1999), provides
evidence for the existence of alternative mechanisms in the clinical
setting.
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